WO2006097535A3 - Peptide agonists of the glucagon family with secretin like activity - Google Patents

Peptide agonists of the glucagon family with secretin like activity Download PDF

Info

Publication number
WO2006097535A3
WO2006097535A3 PCT/EP2006/060853 EP2006060853W WO2006097535A3 WO 2006097535 A3 WO2006097535 A3 WO 2006097535A3 EP 2006060853 W EP2006060853 W EP 2006060853W WO 2006097535 A3 WO2006097535 A3 WO 2006097535A3
Authority
WO
WIPO (PCT)
Prior art keywords
secretin
activity
peptide agonists
glucagon family
glucagon
Prior art date
Application number
PCT/EP2006/060853
Other languages
French (fr)
Other versions
WO2006097535A2 (en
Inventor
Leif Christensen
Ingrid Pettersson
Janos Tiborg Kodra
Original Assignee
Novo Nordisk As
Leif Christensen
Ingrid Pettersson
Janos Tiborg Kodra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Leif Christensen, Ingrid Pettersson, Janos Tiborg Kodra filed Critical Novo Nordisk As
Publication of WO2006097535A2 publication Critical patent/WO2006097535A2/en
Publication of WO2006097535A3 publication Critical patent/WO2006097535A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Abstract

Peptide agonists of the glucagon family with secretin like activity and their therapeutic use.
PCT/EP2006/060853 2005-03-18 2006-03-20 Peptide agonists of the glucagon family with secretin like activity WO2006097535A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05102176 2005-03-18
EP05102176.4 2005-03-18

Publications (2)

Publication Number Publication Date
WO2006097535A2 WO2006097535A2 (en) 2006-09-21
WO2006097535A3 true WO2006097535A3 (en) 2007-04-05

Family

ID=36950819

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/060853 WO2006097535A2 (en) 2005-03-18 2006-03-20 Peptide agonists of the glucagon family with secretin like activity

Country Status (1)

Country Link
WO (1) WO2006097535A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008515856A (en) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ Delayed GLP-1 compound
WO2006037811A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted exendin-4 compounds
ES2550363T3 (en) * 2007-09-05 2015-11-06 Novo Nordisk A/S Truncated GLP-1 derivatives and their therapeutic use
EP2679597A1 (en) 2007-09-05 2014-01-01 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
EP2190460B1 (en) * 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
DK3326620T3 (en) 2010-12-16 2020-05-25 Novo Nordisk As SOLID COMPOSITIONS CONTAINING A GLP-1 AGONIST AND SALT OF N- (8- (2- HYDROXYBENZOYL) AMINO) CAPRYLIC ACID
MX355361B (en) 2011-04-12 2018-04-17 Novo Nordisk As Double-acylated glp-1 derivatives.
JP6396211B2 (en) 2011-07-04 2018-09-26 インペリアル・イノベイションズ・リミテッド New compounds and their effects on feeding behavior
AU2013234496B2 (en) 2012-03-22 2017-07-27 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
HUE042757T2 (en) 2012-03-22 2019-07-29 Novo Nordisk As Compositions comprising a delivery agent and preparation thereof
ES2871328T3 (en) 2012-06-20 2021-10-28 Novo Nordisk As Tablet formulation comprising a peptide and a delivery agent
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
AU2013366691A1 (en) 2012-12-21 2015-07-09 Sanofi Exendin-4 derivatives
TW201609796A (en) 2013-12-13 2016-03-16 賽諾菲公司 Non-acylated EXENDIN-4 peptide analogues
TW201609799A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/GIP receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
IL275778B2 (en) 2018-02-02 2023-12-01 Novo Nordisk As Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043361A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO2001004156A1 (en) * 1999-07-12 2001-01-18 Zealand Pharmaceuticals A/S Peptides that lower blood glucose levels
EP1364967A2 (en) * 1995-03-21 2003-11-26 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364967A2 (en) * 1995-03-21 2003-11-26 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
WO1999043361A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO2001004156A1 (en) * 1999-07-12 2001-01-18 Zealand Pharmaceuticals A/S Peptides that lower blood glucose levels

Also Published As

Publication number Publication date
WO2006097535A2 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
WO2006097535A3 (en) Peptide agonists of the glucagon family with secretin like activity
WO2006097536A3 (en) Dimeric peptide agonists of the glp-1 receptor
WO2006037810A3 (en) Protracted glp-1 compounds
PT1919894E (en) Novel polyquinoline derivatives and the therapeutic use thereof
IL178402A0 (en) 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof
IL186194A0 (en) Markers associated with the therapeutic efficacy of glatiramer acetate
ZA200706254B (en) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same
WO2006037811A3 (en) Protracted exendin-4 compounds
WO2005074524A3 (en) Modified human interferon polypeptides and their uses
AU2006272804A8 (en) Concentrated protein lyophilates, methods, and uses
HK1152055A1 (en) Hyaluronic acid derivative and drug containing the same
WO2006097537A3 (en) Acylated glp-1 compounds
EP1968649A4 (en) Protein nanoparticles and the use of the same
ZA200703876B (en) 2-amido -4-phenylthiazole derivatives, the preparation and therapeutic use thereof
IL177845A0 (en) Combination therapy with glatiramer acetate and riluzole
WO2006131806A3 (en) Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
AP2006003537A0 (en) Use of polypeptides of the cupredoxin family in cancer therapy.
ZA200711105B (en) Novel physiological substance nesfatin substance relevant thereto, and use of the substances
EP1835027A4 (en) Novel cancer antigen peptide and the use thereof
EP1978983A4 (en) Extract of dioscorea sp. and the medical uses thereof
GB0420062D0 (en) Assay methods,materials and preparations
WO2006116311A3 (en) Opioid receptor agonist compounds and their use in treatment of pain
ZA200210316B (en) Composition and its therapeutic use.
IL191067A0 (en) Micronised azodicarbonamide, the preparation and use thereof
EP1829969A4 (en) Novel polypeptide and the use thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06725147

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06725147

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6725147

Country of ref document: EP